羟基喜树碱同步超分割放射治疗Ⅲ期非小细胞肺癌的临床研究  

The clinical comparative study of hydroxycamptothecin combined with concurrent radiotherapy for inoperable stage Ⅲ non-small cell lung cancer

作　　者：李国忠[1] 张绍华[1] 张志[1] 王瑞林[1] 付占昭 

机构地区：[1]河北医科大学附属唐山临床医学院放化疗科,河北唐山063000 [2]秦皇岛市人民医院肿瘤科,066000

出　　处：《临床肿瘤学杂志》2008年第1期15-18,共4页Chinese Clinical Oncology

基　　金：河北省科技攻关课题指导项目(052761861)

摘　　要：目的：探讨羟基喜树碱（HCPT）同步超分割放射治疗Ⅲ期不能手术的非小细胞肺癌（NSCLC）的近期疗效、毒副反应和远期疗效。方法：共入选60例患者，分为治疗组和对照组各30例。治疗组采用同步放化疗，化疗采用HCPT10mg／天，分别于放疗开始和结束的前5天应用，放射治疗采用超分割方法，1．2Gy／次，2次／天，DT62．4～67．2Gy；对照组不给予化疗，放射治疗方法与治疗组相同。结果：58例患者获随访，随访率为96％。治疗组的有效率为76．7％，对照组的有效率为63．3％（P〉0．05）；两组血液学和非血液学的毒副反应比较无统计学差异（P〉0．05）；经Kaplan-Meier生存分析，治疗组和对照组的1、3年预期生存率分别为77．7％、26．1％和70．3％、15．1％（P〉0．05）。结论：HCPT同步超分割放射治疗Ⅲ期不能手术的非小细胞肺癌疗效肯定，与单纯超分割相比较，有一定的增益，但无统计学上的差异，毒副反应可以耐受。Objective：To investigate the efficacy, toxicity and long-term survival of hydroxycamptothecin （HCPT） combined with concurrent radiation therapy for inoperable stage III non-small cell lung cancer（NSCLC）. Methods：Sixty patients were enrolled into this study and divided into treatment group（30 cases） and control group（30 cases）. In treatment group, the patients were admin- istered with HCPT 10mg ＋ NS 250ml, iv. gtt, daily, in the first five days and the last five days during radiation therapy. Thoracic radiation combined with concurrent chemotherapy, 1.2Gy, bid, to a total dose of 62.4-67.2Gy. In control group, it was the same with treatment group except HCPT. The long-term survival was estimated in Kaplan-Meier survival curve. Results：Fifty-eight patients finished the trial. The follow-up rate was 96%. The response rate were 76. 7% and 63. 3% in treatment group and control group respectively （ P 〉 0. 05 ）, and there were the incidence of hematologic and non-hematologic toxicity （ P 〉 0. 05 ）. In long-term survival, 1 -, 3- year survival rate was 77.7%, 26. 1% and 70. 3%, 15.1% in treatment group and control group respectively. There was no significant difference between two groups （P 〉 0. 05）. Conclusion：It is effective on HCPT combined with concurrent hyperfractionated radiation therapy for inoperable stage m NSCLC, and there is some profit comparing hyperfractionated radiation therapy alone and no signifi- cant difference. It was tolerable for toxicity in hematology and non-hematology.

关 键 词：羟基喜树碱 同步放化疗 非小细胞肺癌 超分割放疗 

分 类 号：R730.53[医药卫生—肿瘤] R734.2[医药卫生—临床医学]